The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

BACKGROUND AND AIMS: Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Uschner, Frank Erhard, Schueller, Florian, Nikolova, Ivelina, Klein, Sabine, Schierwagen, Robert, Magdaleno, Fernando, Gröschl, Stefanie, Loosen, Sven, Ritz, Thomas, Roderburg, Christoph, Vucur, Michael, Kristiansen, Glen, Lammers, Twan, Luedde, Tom, Trebicka, Jonel
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6281422/
https://ncbi.nlm.nih.gov/pubmed/30546838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26333
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados